Wednesday, April 5, 2017

Strainprint Technologies Launches Revolutionary New Mobile App For Cannabis Patients

Strainprint Technologies Launches Revolutionary New Mobile App For Cannabis Patients

TORONTO - April 5, 2017 ( Newswire) StrainprintTM Technologies Ltd. ("StrainprintTM") -- a leader in cannabis patient data collection -- is proud to announce the commercial launch of a revolutionary Cannabis Tracking APP & platform. The mobile APP is free for patients and is available for both Apple iOS & Android.
StrainprintTM enables cannabis patients to track and understand the efficacy of their cannabis use by strain, quantity, method of ingestion and dose. Using standardized pain scales, this much-needed data will help patients use cannabis more effectively and help clinicians to better tailor therapeutic regimens. Strainprint's database contains all strains and products available under the Access to Cannabis for Medical Purposes Regulations program (ACMPR). Patients can also add their own unique/personal strains.
"StrainprintTM will help patients and medical practitioners to better understand how specific cannabis genetics and ingestion methods provide the best therapy for over 170 applicable medical conditions," said Alexander Repetski, Chief Communications Officer. "By using individuals' data to fine-tune their treatment, StrainprintTM will assist in improving the quality of life for those using cannabis. This data is also needed by the academic community to accelerate research efforts and to further enhance the understanding of cannabis," he added.
The HIPAA and PIPEDA compliant solution is already identifying valuable and fascinating efficacy trends across a variety of medical conditions. This information will enable patients, producers, clinicians and other supply chain partners to better understand the needs of patients and how specific cannabinoids effect a multitude of conditions.
"The importance of this real-time crowd-sourced data is integral to both governmental bodies and the academic community to accelerate research efforts and further enhance the understanding of cannabis," said StrainprintTM President, David Berg. "With the pending legalization of recreational cannabis in Canada, the data acquired by Strainprint also holds significance in determining many facets of regulations concerning public health and safety," he added.
"StrainprintTM was created out of necessity. As a patient who had limited knowledge about cannabis, the need for a tool to help guide and enhance treatment seemed almost essential. It didn't exist, and that's why we spent several years developing it. We're continually improving the software to ensure a simple and rewarding experience," said Stephanie Karasick, Founder & Chief Strategy Officer.
A new version of the APP will be released in the coming weeks with an exciting Loyalty Program, where users can redeem accumulated points for cannabis-related products and merchandise.
Learn more about Strainprint at:
Connect with Strainprint on Facebook:
Follow us on Twitter: 
Tweet: Strainprint Launches revolutionary mobile app for cannabis patients. #strainprint
About StrainprintTM:
Founded in 2016, StrainprintTM Technologies Ltd. is a Toronto-based company providing enterprise grade analytics and consumer solutions for the medical cannabis industry. StrainprintTM manages the gathering and analysis of real-time cannabis consumption data and ranks specific strain efficacy against conditions and related symptoms. Analyzing anonymous patient treatment data and efficacy measures will help to identify new treatment protocols for the medical community and patients. StrainprintTM also works with commercial producers and clinics to provide advanced intelligence to optimize grow operations and treatment methods.
Media Contact:
Alexander E. Repetski, CCO
Strainprint Technologies Ltd.

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news

Watch the 420 Cannabis Investor video


More Info:

This news is published on the Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

No comments:

Post a Comment